EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Tanvex BioPharma's Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1,675.6 Mil. Therefore, Tanvex BioPharma's EV-to-FCF for today is -6.96.
The historical rank and industry rank for Tanvex BioPharma's EV-to-FCF or its related term are showing as below:
TPE:6541'
s EV-to-FCF Range Over the Past 10 Years
Min: -18.46 Med: -9.13 Max: -4.51
Current: -6.96
During the past 13 years, the highest EV-to-FCF of Tanvex BioPharma was -4.51. The lowest was -18.46. And the median was -9.13.
TPE:6541's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 16.48
vs TPE:6541: -6.96
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tanvex BioPharma's PE Ratio (TTM) for today is calculated as:
Tanvex BioPharma's share price for today is NT$41.40.
Tanvex BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-6.181.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tanvex BioPharma EV-to-FCF Related Terms
Tanvex BioPharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6541 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Tanvex BioPharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's EV-to-FCF falls into.
Tanvex BioPharma's current Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1,675.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma (TPE:6541) has a EV-to-FCF of -6.96 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tanvex BioPharma and its competitors. According to the industry distribution chart, Tanvex BioPharma ranks #999999 out of 331 companies in the Biotechnology industry.
Is Tanvex BioPharma's EV-to-FCF too high?
Tanvex BioPharma's current EV-to-FCF is -6.96. Based on the distribution chart, Tanvex BioPharma ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #999999 out of 331 companies for EV-to-FCF. This places Tanvex BioPharma in the lower half of its industry. The industry median EV-to-FCF is 16.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.48, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tanvex BioPharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tanvex BioPharma's current EV-to-FCF is -6.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current EV-to-FCF is -6.96. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current EV-to-FCF is -6.96 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?
Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued.
The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61.
GuruFocus considers Tanvex BioPharma to be Possible Value Trap.
Key valuation signals for TPE:6541:
EV-to-FCF: -6.96
GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score
Get the complete analysis for TPE:6541
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
